IL17A and cancer: Although γδ T cells were identified as a prognostic marker for better outcomes16 and recently shown to be effectors of immunotherapy in DNA mismatch repair-deficient cancers with HLA class I defects86, other studies report the potential negative impact of IL-17-producing γδ T cells34–36.